{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:25Z","timestamp":1792788205897,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Labex EpiGenMed","award":["ANR-10-LABX-12-01"],"award-info":[{"award-number":["ANR-10-LABX-12-01"]}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["2012-109\/087437 and PLBIO15-256"],"award-info":[{"award-number":["2012-109\/087437 and PLBIO15-256"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002887","name":"Conseil R\u00e9gional Languedoc-Roussillon","doi-asserted-by":"publisher","award":["R14026FF"],"award-info":[{"award-number":["R14026FF"]}],"id":[{"id":"10.13039\/501100002887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","award":["201400047510"],"award-info":[{"award-number":["201400047510"]}],"id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SIRIC Montpellier","award":["INCa-DGOS-Inserm 6045"],"award-info":[{"award-number":["INCa-DGOS-Inserm 6045"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13148-018-0554-4","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T06:46:45Z","timestamp":1538549205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs"],"prefix":"10.1186","volume":"10","author":[{"given":"Laurie","family":"Herviou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alboukadel","family":"Kassambara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Boireau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Requirand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Moreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,3]]},"reference":[{"key":"554_CR1","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.18632\/oncotarget.6198","volume":"7","author":"L Herviou","year":"2016","unstructured":"Herviou L, Cavalli G, Cartron G, Klein B, Moreaux J. EZH2 in normal hematopoiesis and hematological malignancies. Oncotarget. 2016;7:2284.","journal-title":"Oncotarget"},{"key":"554_CR2","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","volume":"124","author":"B Barlogie","year":"2014","unstructured":"Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124:3043\u201351.","journal-title":"Blood"},{"key":"554_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91\u2013101.","journal-title":"Cancer Cell"},{"key":"554_CR4","doi-asserted-by":"publisher","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5. https:\/\/doi.org\/10.1038\/ncomms3997 .","DOI":"10.1038\/ncomms3997"},{"key":"554_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET Bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904\u201317.","journal-title":"Cell"},{"key":"554_CR6","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/bjc.2013.392","volume":"109","author":"J Moreaux","year":"2013","unstructured":"Moreaux J, Reme T, Leonard W, Veyrune J-L, Requirand G, Goldschmidt H, et al. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br J Cancer. 2013;109:676\u201385.","journal-title":"Br J Cancer"},{"key":"554_CR7","doi-asserted-by":"publisher","first-page":"e11483","DOI":"10.1371\/journal.pone.0011483","volume":"5","author":"A Kalushkova","year":"2010","unstructured":"Kalushkova A, Frykn\u00e4s M, Lemaire M, Fristedt C, Agarwal P, Eriksson M, et al. Polycomb target genes are silenced in multiple myeloma. PLoS One. 2010;5:e11483.","journal-title":"PLoS One"},{"key":"554_CR8","doi-asserted-by":"publisher","first-page":"6269","DOI":"10.1038\/sj.onc.1208771","volume":"24","author":"PA Croonquist","year":"2005","unstructured":"Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene. 2005;24:6269\u201380.","journal-title":"Oncogene"},{"key":"554_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.tox.2009.10.023","volume":"267","author":"F Zhao","year":"2010","unstructured":"Zhao F, Chen Y, Li R, Liu Y, Wen L, Zhang C. Triptolide alters histone H3K9 and H3K27 methylation state and induces G0\/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. Toxicology. 2010;267:70\u20139.","journal-title":"Toxicology"},{"key":"554_CR10","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.18632\/oncotarget.6843","volume":"7","author":"P Agarwal","year":"2016","unstructured":"Agarwal P, Alzrigat M, P\u00e1rraga AA, Enroth S, Singh U, Ungerstedt J, et al. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of polycomb gene targeting and highlights EZH2 as a potential therapeutic target. Oncotarget. 2016;7:6809.","journal-title":"Oncotarget"},{"key":"554_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/1535-7163.MCT-15-0486","volume":"15","author":"H Hernando","year":"2016","unstructured":"Hernando H, Gelato KA, Lesche R, Beckmann G, Koehr S, Otto S, et al. EZH2 inhibition blocks multiple myeloma cell growth through upregulation of epithelial tumor suppressor genes. Mol Cancer Ther. 2016;15:287\u201398.","journal-title":"Mol Cancer Ther"},{"key":"554_CR12","doi-asserted-by":"crossref","unstructured":"Alzrigat M, P\u00e1rraga AA, Agarwal P, Zureigat H, \u00d6sterborg A, Nahi H, et al. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. OncoTarget. 2016. https:\/\/www.researchgate.net\/profile\/Mohammad_Alzrigat\/publication\/312021585_EZH2_inhibition_in_multiple_myeloma_downregulates_myeloma_associated_oncogenes_and_upregulates_microRNAs_with_potential_tumor_suppressor_functions\/links\/58694b7008ae8fce4917d807.pdf . Accessed 6 Apr 2017.","DOI":"10.18632\/oncotarget.14378"},{"key":"554_CR13","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1038\/bcj.2017.27","volume":"7","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn C, Bright MD, Buros AF, Stein CK, Walters Z, Aronson LI, et al. Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. Blood Cancer J. 2017;7:e549.","journal-title":"Blood Cancer J"},{"issue":"3","key":"554_CR14","doi-asserted-by":"publisher","first-page":"e26218","DOI":"10.1002\/pbc.26218","volume":"64","author":"Raushan T. Kurmasheva","year":"2016","unstructured":"Kurmasheva RT, Sammons M, Favours E, Wu J, Kurmashev D, Cosmopoulos K, et al. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the pediatric preclinical testing program: Kurmasheva et al. Pediatr Blood Cancer 2016. doi: https:\/\/doi.org\/10.1002\/pbc.26218 .","journal-title":"Pediatric Blood & Cancer"},{"key":"554_CR15","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3324\/haematol.2010.033456","volume":"96","author":"J Moreaux","year":"2011","unstructured":"Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011;96:574\u201382.","journal-title":"Haematologica"},{"key":"554_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2010.030296","volume":"96","author":"D Hose","year":"2011","unstructured":"Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica. 2011;96:87\u201395.","journal-title":"Haematologica"},{"key":"554_CR17","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1182\/blood-2008-09-178350","volume":"113","author":"D Hose","year":"2009","unstructured":"Hose D, R\u00e8me T, Meissner T, Moreaux J, Seckinger A, Lewis J, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood. 2009;113:4331\u201340.","journal-title":"Blood"},{"key":"554_CR18","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","volume":"107","author":"B Barlogie","year":"2006","unstructured":"Barlogie B. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107:2633\u20138.","journal-title":"Blood"},{"key":"554_CR19","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/leu.2008.99","volume":"22","author":"M Pineda-Roman","year":"2008","unstructured":"Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, et al. VTD combination therapy with bortezomib\u2013thalidomide\u2013dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia. 2008;22:1419\u201327.","journal-title":"Leukemia"},{"key":"554_CR20","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","volume":"109","author":"G Mulligan","year":"2007","unstructured":"Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109:3177\u201388.","journal-title":"Blood"},{"key":"554_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"554_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2004-5-10-r80","volume":"5","author":"RC Gentleman","year":"2004","unstructured":"Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:1.","journal-title":"Genome Biol"},{"key":"554_CR23","doi-asserted-by":"publisher","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 .","DOI":"10.1186\/s13059-014-0550-8"},{"key":"554_CR24","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739\u201340.","journal-title":"Bioinformatics"},{"key":"554_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci"},{"key":"554_CR26","doi-asserted-by":"publisher","first-page":"e1004077","DOI":"10.1371\/journal.pcbi.1004077","volume":"11","author":"A Kassambara","year":"2015","unstructured":"Kassambara A, R\u00e8me T, Jourdan M, Fest T, Hose D, Tarte K, et al. GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells. PLoS Comput Biol. 2015;11:e1004077.","journal-title":"PLoS Comput Biol"},{"key":"554_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nbt.3051","volume":"33","author":"R K\u00fcffner","year":"2014","unstructured":"K\u00fcffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2014;33:51\u20137.","journal-title":"Nat Biotechnol"},{"key":"554_CR28","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/1535-7163.MCT-12-0721","volume":"11","author":"J Moreaux","year":"2012","unstructured":"Moreaux J, Reme T, Leonard W, Veyrune J-L, Requirand G, Goldschmidt H, et al. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors. Mol Cancer Ther. 2012;11:2685\u201392.","journal-title":"Mol Cancer Ther"},{"key":"554_CR29","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","volume":"30","author":"MJ Aryee","year":"2014","unstructured":"Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014;30:1363\u20139.","journal-title":"Bioinformatics"},{"issue":"8","key":"554_CR30","doi-asserted-by":"publisher","first-page":"e1003118","DOI":"10.1371\/journal.pcbi.1003118","volume":"9","author":"Michael Lawrence","year":"2013","unstructured":"Lawrence M, Huber W, Pag\u00e8s H, Aboyoun P, Carlson M, Gentleman R, et al. Software for computing and annotating genomic ranges. PLoS Comput Biol. 2013;9. https:\/\/doi.org\/10.1371\/journal.pcbi.1003118 .","journal-title":"PLoS Computational Biology"},{"key":"554_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","volume":"43","author":"T Hothorn","year":"2003","unstructured":"Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal. 2003;43:121\u201337.","journal-title":"Comput Stat Data Anal"},{"key":"554_CR32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/hon.2438_13","volume":"35","author":"TE Cummin","year":"2017","unstructured":"Cummin TE, Araf S, Du M, Barrans S, Bentley MA, Clipson A, et al. Prognostic significance and correlation to gene expression profile of EZH2 mutations in diffuse large b-cell lymphoma (DLBL) in 2 large prospective studies. Hematol Oncol. 2017;35:158\u20139.","journal-title":"Hematol Oncol"},{"key":"554_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ceb.2015.10.004","volume":"37","author":"AA Guirguis","year":"2015","unstructured":"Guirguis AA, Ebert BL. Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond. Curr Opin Cell Biol. 2015;37:61\u20137.","journal-title":"Curr Opin Cell Biol"},{"key":"554_CR34","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1038\/bcj.2015.66","volume":"5","author":"CC Bjorklund","year":"2015","unstructured":"Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, et al. Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015;5:e354.","journal-title":"Blood Cancer J"},{"key":"554_CR35","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.celrep.2017.09.078","volume":"21","author":"T Ezponda","year":"2017","unstructured":"Ezponda T, Dup\u00e9r\u00e9-Richer D, Will CM, Small EC, Varghese N, Patel T, et al. UTX\/KDM6A loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition. Cell Rep. 2017;21:628\u201340.","journal-title":"Cell Rep"},{"key":"554_CR36","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.chembiol.2013.09.013","volume":"20","author":"S Garapaty-Rao","year":"2013","unstructured":"Garapaty-Rao S, Nasveschuk C, Gagnon A, Chan EY, Sandy P, Busby J, et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol. 2013;20:1329\u201339.","journal-title":"Chem Biol"},{"key":"554_CR37","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nature04431","volume":"439","author":"E Vir\u00e9","year":"2005","unstructured":"Vir\u00e9 E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2005;439:871\u20134.","journal-title":"Nature"},{"key":"554_CR38","first-page":"4535","volume":"59","author":"M Toyota","year":"1999","unstructured":"Toyota M, Ho C, Ohe-Toyota M, Baylin SB, Issa J-PJ. Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5\u2032 CpG island in human tumors. Cancer Res. 1999;59:4535\u201341.","journal-title":"Cancer Res"},{"key":"554_CR39","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/bjc.2016.176","volume":"115","author":"Y Cha","year":"2016","unstructured":"Cha Y, Kim K-J, Han S-W, Rhee YY, Bae JM, Wen X, et al. Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. Br J Cancer. 2016;115:164\u201371.","journal-title":"Br J Cancer"},{"key":"554_CR40","doi-asserted-by":"publisher","unstructured":"Ohkubo T. T-type voltage-activated calcium channel Cav3.1, but not Cav3.2, is involved in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells. Int J Oncol. 2012. https:\/\/doi.org\/10.3892\/ijo.2012.1422 .","DOI":"10.3892\/ijo.2012.1422"},{"key":"554_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.exer.2007.10.010","volume":"86","author":"Y Cohen","year":"2008","unstructured":"Cohen Y, Merhavi-Shoham E, Avraham RB, Frenkel S, Pe\u2019er J, Goldenberg-Cohen N. Hypermethylation of CpG island loci of multiple tumor suppressor genes in retinoblastoma. Exp Eye Res. 2008;86:201\u20136.","journal-title":"Exp Eye Res"},{"key":"554_CR42","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1128\/MCB.01866-07","volume":"28","author":"CM Bailey","year":"2008","unstructured":"Bailey CM, Abbott DE, Margaryan NV, Khalkhali-Ellis Z, Hendrix MJC. Interferon regulatory factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner. Mol Cell Biol. 2008;28:2235\u201343.","journal-title":"Mol Cell Biol"},{"key":"554_CR43","doi-asserted-by":"publisher","first-page":"e0132757","DOI":"10.1371\/journal.pone.0132757","volume":"10","author":"T Zengin","year":"2015","unstructured":"Zengin T, Ekinci B, Kucukkose C, Yalcin-Ozuysal O. IRF6 is involved in the regulation of cell proliferation and transformation in MCF10A cells downstream of notch signaling. PLoS One. 2015;10:e0132757.","journal-title":"PLoS One"},{"key":"554_CR44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4161\/cam.5.5.17949","volume":"5","author":"LA Mostovich","year":"2011","unstructured":"Mostovich LA, Prudnikova TY, Kondratov AG, Loginova D, Vavilov PV, Rykova VI, et al. Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors. Cell Adhes Migr. 2011;5:395\u2013401.","journal-title":"Cell Adhes Migr"},{"key":"554_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4161\/epi.24233","volume":"8","author":"VN Senchenko","year":"2013","unstructured":"Senchenko VN, Kisseljova NP, Ivanova TA, Dmitriev AA, Krasnov GS, Kudryavtseva AV, et al. Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer. Epigenetics. 2013;8:409\u201320.","journal-title":"Epigenetics"},{"key":"554_CR46","doi-asserted-by":"publisher","first-page":"31493","DOI":"10.18632\/oncotarget.5154","volume":"6","author":"I Nawaz","year":"2015","unstructured":"Nawaz I, Hu L-F, Du Z-M, Moumad K, Ignatyev I, Pavlova TV, et al. Integrin \u03b19 gene promoter is hypermethylated and downregulated in nasopharyngeal carcinoma. Oncotarget. 2015;6:31493.","journal-title":"Oncotarget"},{"key":"554_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2007.06.034","volume":"130","author":"M Mumby","year":"2007","unstructured":"Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell. 2007;130:21\u20134.","journal-title":"Cell"},{"key":"554_CR48","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1541-7786.MCR-12-0710","volume":"11","author":"EG Bluemn","year":"2013","unstructured":"Bluemn EG, Spencer ES, Mecham B, Gordon RR, Coleman I, Lewinshtein D, et al. PPP2R2C loss promotes castration-resistance and is associated with increased prostate Cancer-specific mortality. Mol Cancer Res. 2013;11:568\u201378.","journal-title":"Mol Cancer Res"},{"key":"554_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.biopha.2016.03.043","volume":"81","author":"D Bi","year":"2016","unstructured":"Bi D, Ning H, Liu S, Que X, Ding K. miR-1301 promotes prostate cancer proliferation through directly targeting PPP2R2C. Biomed Pharmacother. 2016;81:25\u201330.","journal-title":"Biomed Pharmacother"},{"key":"554_CR50","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.biopha.2015.12.005","volume":"77","author":"A-H Wu","year":"2016","unstructured":"Wu A-H, Huang Y, Zhang L-Z, Tian G, Liao Q-Z, Chen S-L. MiR-572 prompted cell proliferation of human ovarian cancer cells by suppressing PPP2R2C expression. Biomed Pharmacother. 2016;77:92\u20137.","journal-title":"Biomed Pharmacother"},{"key":"554_CR51","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1016\/j.febslet.2013.09.029","volume":"587","author":"Y Fan","year":"2013","unstructured":"Fan Y, Chen L, Wang J, Yao Q, Wan J. Over expression of PPP2R2C inhibits human glioma cells growth through the suppression of mTOR pathway. FEBS Lett. 2013;587:3892\u20137.","journal-title":"FEBS Lett"},{"key":"554_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.cca.2016.10.008","volume":"463","author":"Y Sugita","year":"2016","unstructured":"Sugita Y, Ohwada C, Kawaguchi T, Muto T, Tsukamoto S, Takeda Y, et al. Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: a multicenter prospective analysis. Clin Chim Acta. 2016;463:47\u201352.","journal-title":"Clin Chim Acta"},{"key":"554_CR53","doi-asserted-by":"publisher","unstructured":"Krzeminski P, Corchete LA, Garc\u00eda JL, L\u00f3pez-Corral L, Fermi\u00f1\u00e1n E, Garc\u00eda EM, et al. Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse. Oncotarget. 2016. https:\/\/doi.org\/10.18632\/oncotarget.13025 .","DOI":"10.18632\/oncotarget.13025"},{"key":"554_CR54","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1093\/carcin\/bgm124","volume":"28","author":"MV Guijarro","year":"2007","unstructured":"Guijarro MV, Leal JFM, Blanco-Aparicio C, Alonso S, Fominaya J, Lleonart M, et al. MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis. 2007;28:2096\u2013104.","journal-title":"Carcinogenesis"},{"key":"554_CR55","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1242\/jcs.01639","volume":"118","author":"C Wu","year":"2005","unstructured":"Wu C. Migfilin and its binding partners: from cell biology to human diseases. J Cell Sci. 2005;118:659\u201364.","journal-title":"J Cell Sci"},{"key":"554_CR56","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/aps.2012.123","volume":"33","author":"J Fan","year":"2012","unstructured":"Fan J, Ou Y, Wu C, Yu C, Song Y, Zhan Q. Migfilin sensitizes cisplatin-induced apoptosis in human glioma cells in vitro. Acta Pharmacol Sin. 2012;33:1301\u201310.","journal-title":"Acta Pharmacol Sin"},{"key":"554_CR57","first-page":"1977","volume":"33","author":"V Gkretsi","year":"2013","unstructured":"Gkretsi V, Papanikolaou V, Zacharia LC, Athanassiou E, Wu C, Tsezou A. Mitogen-inducible Gene-2 (MIG2) and migfilin expression is reduced in samples of human breast cancer. Anticancer Res. 2013;33:1977\u201381.","journal-title":"Anticancer Res"},{"key":"554_CR58","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s13277-015-3886-0","volume":"37","author":"H Ma","year":"2016","unstructured":"Ma H, Wang L, Zhang T, Shen H, Du J. Loss of \u03b2-arrestin1 expression predicts unfavorable prognosis for non-small cell lung cancer patients. Tumor Biol. 2016;37:1341\u20137.","journal-title":"Tumor Biol"},{"issue":"2","key":"554_CR59","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3892\/or.2016.5337","volume":"37","author":"Hongchang Shen","year":"2016","unstructured":"Shen H, Wang L, Zhang J, Dong W, Zhang T, Ni Y, et al. ARRB1 enhances the chemosensitivity of lung cancer through the mediation of DNA damage response. Oncol Rep. 2016. https:\/\/doi.org\/10.3892\/or.2016.5337 .","journal-title":"Oncology Reports"},{"key":"554_CR60","doi-asserted-by":"publisher","first-page":"11611","DOI":"10.1007\/s13277-016-5112-0","volume":"37","author":"A Kumar","year":"2016","unstructured":"Kumar A, Bhanja A, Bhattacharyya J, Jaganathan BG. Multiple roles of CD90 in cancer. Tumor Biol. 2016;37:11611\u201322.","journal-title":"Tumor Biol"},{"key":"554_CR61","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","volume":"117","author":"M Cavo","year":"2011","unstructured":"Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, et al. International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063\u201373.","journal-title":"Blood"},{"key":"554_CR62","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","volume":"30","author":"KC Anderson","year":"2012","unstructured":"Anderson KC. The 39th David a. Karnofsky lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012;30:445\u201352.","journal-title":"J Clin Oncol"},{"key":"554_CR63","doi-asserted-by":"publisher","first-page":"e1004696","DOI":"10.1371\/journal.pcbi.1004696","volume":"12","author":"A M\u00e9ndez","year":"2016","unstructured":"M\u00e9ndez A, Mendoza L. A network model to describe the terminal differentiation of B cells. PLoS Comput Biol. 2016;12:e1004696.","journal-title":"PLoS Comput Biol"},{"key":"554_CR64","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3109\/10428194.2014.953155","volume":"56","author":"M Boi","year":"2015","unstructured":"Boi M, Zucca E, Inghirami G, Bertoni F. PRDM1 \/BLIMP1: a tumor suppressor gene in B and T cell lymphomas. Leuk Lymphoma. 2015;56:1223\u20138.","journal-title":"Leuk Lymphoma"},{"key":"554_CR65","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/eji.201141553","volume":"41","author":"J Alinikula","year":"2011","unstructured":"Alinikula J, Nera K-P, Junttila S, Lassila O. Alternate pathways for Bcl6-mediated regulation of B cell to plasma cell differentiation. Eur J Immunol. 2011;41:2404\u201313.","journal-title":"Eur J Immunol"},{"key":"554_CR66","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.bbrc.2016.05.067","volume":"475","author":"Y Inagaki","year":"2016","unstructured":"Inagaki Y, Hayakawa F, Hirano D, Kojima Y, Morishita T, Yasuda T, et al. PAX5 tyrosine phosphorylation by SYK co-operatively functions with its serine phosphorylation to cancel the PAX5-dependent repression of BLIMP1: a mechanism for antigen-triggered plasma cell differentiation. Biochem Biophys Res Commun. 2016;475:176\u201381.","journal-title":"Biochem Biophys Res Commun"},{"key":"554_CR67","doi-asserted-by":"publisher","first-page":"20130074","DOI":"10.1098\/rsfs.2013.0074","volume":"4","author":"G Yao","year":"2014","unstructured":"Yao G. Modelling mammalian cellular quiescence. Interface Focus. 2014;4:20130074.","journal-title":"Interface Focus"},{"key":"554_CR68","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/sj.onc.1206145","volume":"22","author":"S Wu","year":"2003","unstructured":"Wu S, Cetinkaya C, Munoz-Alonso MJ, von der Lehr N, Bahram F, Beuger V, et al. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene. 2003;22:351\u201360.","journal-title":"Oncogene"},{"key":"554_CR69","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.bbagrm.2014.03.013","volume":"1849","author":"G Bretones","year":"2015","unstructured":"Bretones G, Delgado MD, Le\u00f3n J. Myc and cell cycle control. Biochim Biophys Acta BBA - Gene Regul Mech. 2015;1849:506\u201316.","journal-title":"Biochim Biophys Acta BBA - Gene Regul Mech"},{"key":"554_CR70","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2014-03-559591","volume":"124","author":"J-F Fecteau","year":"2014","unstructured":"Fecteau J-F, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon\/p21WAF1\/Cip1-dependent mechanism independent of functional p53. Blood. 2014;124:1637\u201344.","journal-title":"Blood"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-018-0554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-018-0554-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-018-0554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T18:07:30Z","timestamp":1605118050000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-018-0554-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,3]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["554"],"URL":"https:\/\/doi.org\/10.1186\/s13148-018-0554-4","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,3]]},"assertion":[{"value":"9 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BM of patients presenting with previously untreated MM at the university hospital of Montpellier was obtained after patients\u2019 written informed consent in accordance with the Declaration of Helsinki and agreement of the Montpellier University Hospital Centre for Biological Resources (DC-2008-417).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"121"}}